デフォルト表紙
市場調査レポート
商品コード
1243273

ゲノム編集/ゲノム工学の世界市場

Genome Editing / Genome Engineering

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.62円
ゲノム編集/ゲノム工学の世界市場
出版日: 2023年03月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ゲノム編集/ゲノム工学の世界市場は2030年に343億米ドルに達する

COVID-19後の変化したビジネス環境において、2022年に80億米ドルと推定されるゲノム編集/ゲノム工学の世界市場は、2022年から2030年にかけてCAGR 19.9%の成長で、2030年までに343億米ドルの改定規模に達すると予測されます。本レポートで分析したセグメントの1つであるCRISPRは、CAGR22.4%を記録し、分析期間終了時には169億米ドルに達すると予測されます。パンデミック後の回復が進んでいることを考慮し、ZFNセグメントの成長は、今後8年間のCAGRが15%に修正されました。

米国市場は25億米ドル、中国はCAGR19.2%で成長すると予測されています。

米国のゲノム編集/ゲノム工学市場は、2022年には25億米ドルになると推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが19.2%となり、2030年には58億米ドルの市場規模に達すると予測されます。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ17.4%と16.4%の成長が予測されています。欧州では、ドイツがCAGR13.5%で成長すると予測されています。

調査対象企業の例

  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies(IDT), Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Sangamo Therapeutics
  • Thermo Fisher Scientific, Inc.
  • Transposagen Biopharmaceuticals, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP12163

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Genome Editing / Genome Engineering Market to Reach $34.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Genome Editing / Genome Engineering estimated at US$8 Billion in the year 2022, is projected to reach a revised size of US$34.3 Billion by 2030, growing at aCAGR of 19.9% over the period 2022-2030. CRISPR, one of the segments analyzed in the report, is projected to record 22.4% CAGR and reach US$16.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the ZFN segment is readjusted to a revised 15% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.5 Billion, While China is Forecast to Grow at 19.2% CAGR

The Genome Editing / Genome Engineering market in the U.S. is estimated at US$2.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 19.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.4% and 16.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

Select Competitors (Total 27 Featured) -

  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies (IDT), Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Sangamo Therapeutics
  • Thermo Fisher Scientific, Inc.
  • Transposagen Biopharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Genome Editing / Genome Engineering - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for CRISPR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for CRISPR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for TALEN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for TALEN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for ZFN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for ZFN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 11: World Genome Editing / Genome Engineering Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Ex-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 13: World 8-Year Perspective for Ex-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for In-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World 8-Year Perspective for In-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Genetic Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World 8-Year Perspective for Genetic Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Clinical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 19: World 8-Year Perspective for Clinical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World 8-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 25: World 8-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 29: USA 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 31: USA 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Canada 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Canada 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 41: Canada 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • JAPAN
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 43: Japan 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Japan 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Japan 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • CHINA
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 53: China 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 55: China 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: China 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • EUROPE
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 59: Europe 8-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 61: Europe 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Europe 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Europe 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Europe 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • FRANCE
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: France 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 71: France 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 73: France 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: France 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • GERMANY
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 77: Germany 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 79: Germany 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Germany 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 83: Germany 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • ITALY
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 85: Italy 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Italy 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 89: Italy 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 91: Italy 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • UNITED KINGDOM
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: UK 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 94: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 95: UK 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 97: UK 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: UK 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 101: Rest of Europe 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 109: Asia-Pacific 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Rest of World 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 119: Rest of World 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 121: Rest of World 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Rest of World 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

IV. COMPETITION